[1] Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev, 2017,49(2):197-211.
[2] Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol, 2018,68(2):268-279.
[3] Younossi ZM, Golabi P, Paik JM, et.al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology,2023,77(4):1335-1347.
[4] Li J, Zou B, Yeo YH, et.al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol,2019,4(5):389-398.
[5] Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLD in China rrom 2008 to 2018: A systematic review and Meta-analysis. Hepatology, 2019,70(4):1119-1133.
[6] Eslam M, Newsome PN, Sarin SK, et.al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol, 2020,73(1):202-209.
[7] Eslam M, Sanyal AJ, George J. International Consensus Panel. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 2020,158(7):1999-2014,e1.
[8] Anstee QM, Reeves HL, Kotsiliti E, et al. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol, 2019,16(7):411-428.
[9] Bengtsson B, Stål P, Wahlin S, et.al. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis. Liver Int, 2019,39(6):1098-1108.
[10] Stine JG, Wentworth BJ, Zimmet A, et.al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther,2018,48(7):696-703.
[11] Piscaglia F, Svegliati-Baroni G, Barchetti A, et.al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology,2016,63(3):827-838.
[12] Llovet JM, Willoughby CE, Singal AG, et al. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nat Rev Gastroenterol Hepatol, 2023,20(8):487-503.
[13] Cernea S, Oni or D. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma. World J Gastroenterol,2023,29(2):286-309.
[14] Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol, 2018,69(4):896-904.
[15] Wolf E, Rich NE, Marrero JA, et al. Use of hepatocellular carcinoma surveillance in patients with cirrhosis: A systematic review and Meta-analysis. Hepatology, 2021,73(2):713-725.
[16] Singal AG, Haaland B, Parikh ND, et al. Comparison of a multitarget blood test to ultrasound and alpha-fetoprotein for hepatocellular carcinoma surveillance: Results of a network meta-analysis. Hepatol Commun, 2022,6(10):2925-2936.
[17] Norero B, Dufour JF. Should we undertake surveillance for HCC in patients with MAFLD? Ther Adv Endocrinol Metab, 2023,14:20420188231160389.
[18] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol,2018,69(1):182-236.
[19] Huang DQ, Wilson LA, Behling C, et.al. Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: A multicenter study. Gastroenterology,2023,165(2):463-472,e5.
[20] Kim MN, Han K, Yoo J, et al. Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients. Int J Cancer, 2023,153(8):1448-1458.
[21] Yun B, Ahn SH, Oh J, et al. Effect of metabolic dysfunction-associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study. Hepatol Res, 2022,52(12):975-984.
[22] Rios RS, Zheng KI, Targher G, et al. Non-invasive fibrosis assessment in non-alcoholic fatty liver disease. Chin Med J (Engl), 2020,133(22):2743-2745.
[23] Angulo P, Hui JM, Marchesini G, et.al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 2007,45(4):846-854.
[24] Cholankeril G, Kramer JR, Chu J, et al. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. J Hepatol, 2023,78(3):493-500.
[25] Pugliese N, Alfarone L, Arcari I, et.al. Clinical features and management issues of NAFLD-related HCC: what we know so far. Expert Rev Gastroenterol Hepatol, 2023,17(1):31-43.
[26] Wong VW, Irles M, Wong GL, et al. Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. Gut, 2019,68(11):2057-2064.
[27] Santi V, Trevisani F, Gramenzi A, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol, 2010,53(2):291-297.
[28] Pelizzaro F, Peserico G, D'Elia M, et al. Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. Dig Liver Dis, 2022,54(7):927-936.
[29] Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol, 2016,64(4):800-806.
[30] Chen X, Gole J, Gore A, et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nat Commun,2020,21;11(1):3475.
[31] Best J, Bechmann LP, Sowa JP, et al. GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol, 2020,18(3):728-735,e4. |
